These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

189 related items for PubMed ID: 11455061

  • 1. A recombinant IgG3-(IL-2) fusion protein for the treatment of human HER2/neu expressing tumors.
    Penichet ML, Dela Cruz JS, Shin SU, Morrison SL.
    Hum Antibodies; 2001; 10(1):43-9. PubMed ID: 11455061
    [Abstract] [Full Text] [Related]

  • 2. Recombinant anti-human HER2/neu IgG3-(GM-CSF) fusion protein retains antigen specificity and cytokine function and demonstrates antitumor activity.
    Dela Cruz JS, Trinh KR, Morrison SL, Penichet ML.
    J Immunol; 2000 Nov 01; 165(9):5112-21. PubMed ID: 11046042
    [Abstract] [Full Text] [Related]

  • 3. Vaccination with novel combinations of anti-HER2/neu cytokines fusion proteins and soluble protein antigen elicits a protective immune response against HER2/neu expressing tumors.
    Helguera G, Dela Cruz JS, Lowe C, Ng PP, Trinh R, Morrison SL, Penichet ML.
    Vaccine; 2006 Jan 16; 24(3):304-16. PubMed ID: 16125282
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Insights into the mechanism of anti-tumor immunity in mice vaccinated with the human HER2/neu extracellular domain plus anti-HER2/neu IgG3-(IL-2) or anti-HER2/neu IgG3-(GM-CSF) fusion protein.
    Dela Cruz JS, Morrison SL, Penichet ML.
    Vaccine; 2005 Sep 15; 23(39):4793-803. PubMed ID: 15967544
    [Abstract] [Full Text] [Related]

  • 7. A single-chain IL-12 IgG3 antibody fusion protein retains antibody specificity and IL-12 bioactivity and demonstrates antitumor activity.
    Peng LS, Penichet ML, Morrison SL.
    J Immunol; 1999 Jul 01; 163(1):250-8. PubMed ID: 10384123
    [Abstract] [Full Text] [Related]

  • 8. Polymalic acid nanobioconjugate for simultaneous immunostimulation and inhibition of tumor growth in HER2/neu-positive breast cancer.
    Ding H, Helguera G, Rodríguez JA, Markman J, Luria-Pérez R, Gangalum P, Portilla-Arias J, Inoue S, Daniels-Wells TR, Black K, Holler E, Penichet ML, Ljubimova JY.
    J Control Release; 2013 Nov 10; 171(3):322-9. PubMed ID: 23770212
    [Abstract] [Full Text] [Related]

  • 9. In vivo properties of three human HER2/neu-expressing murine cell lines in immunocompetent mice.
    Penichet ML, Challita PM, Shin SU, Sampogna SL, Rosenblatt JD, Morrison SL.
    Lab Anim Sci; 1999 Apr 10; 49(2):179-88. PubMed ID: 10331548
    [Abstract] [Full Text] [Related]

  • 10. Delivery of NKG2D ligand using an anti-HER2 antibody-NKG2D ligand fusion protein results in an enhanced innate and adaptive antitumor response.
    Cho HM, Rosenblatt JD, Tolba K, Shin SJ, Shin DS, Calfa C, Zhang Y, Shin SU.
    Cancer Res; 2010 Dec 15; 70(24):10121-30. PubMed ID: 21159634
    [Abstract] [Full Text] [Related]

  • 11. Targeted delivery of tumor antigens to activated dendritic cells via CD11c molecules induces potent antitumor immunity in mice.
    Wei H, Wang S, Zhang D, Hou S, Qian W, Li B, Guo H, Kou G, He J, Wang H, Guo Y.
    Clin Cancer Res; 2009 Jul 15; 15(14):4612-21. PubMed ID: 19584156
    [Abstract] [Full Text] [Related]

  • 12. Decreased survival of human breast cancer cells expressing HER2/neu on in vitro incubation with an anti-HER2/neu antibody fused to C5a or C5a desArg.
    Fuenmayor J, Perez-Vazquez K, Perez-Witzke D, Penichet ML, Montano RF.
    Mol Cancer Ther; 2010 Aug 15; 9(8):2175-85. PubMed ID: 20682652
    [Abstract] [Full Text] [Related]

  • 13. Intraoperative imaging of metastatic lymph nodes using a fluorophore-conjugated antibody in a HER2/neu-expressing orthotopic breast cancer mouse model.
    Wu J, Ma R, Cao H, Wang Z, Jing C, Sun Y, Zhang Y, Yang Z, Hoffman RM, Tang J.
    Anticancer Res; 2013 Feb 15; 33(2):419-24. PubMed ID: 23393332
    [Abstract] [Full Text] [Related]

  • 14. Construction and characterization of novel, recombinant immunotoxins targeting the Her2/neu oncogene product: in vitro and in vivo studies.
    Cao Y, Marks JD, Marks JW, Cheung LH, Kim S, Rosenblum MG.
    Cancer Res; 2009 Dec 01; 69(23):8987-95. PubMed ID: 19934334
    [Abstract] [Full Text] [Related]

  • 15. A trimeric anti-HER2/neu ScFv and tumor necrosis factor-alpha fusion protein induces HER2/neu signaling and facilitates repair of injured epithelia.
    Huang TH, Morrison SL.
    J Pharmacol Exp Ther; 2006 Mar 01; 316(3):983-91. PubMed ID: 16291729
    [Abstract] [Full Text] [Related]

  • 16. Targeting IFN-alpha to B cell lymphoma by a tumor-specific antibody elicits potent antitumor activities.
    Huang TH, Chintalacharuvu KR, Morrison SL.
    J Immunol; 2007 Nov 15; 179(10):6881-8. PubMed ID: 17982079
    [Abstract] [Full Text] [Related]

  • 17. Potent inhibition of human gastric cancer by HER2-directed induction of apoptosis with anti-HER2 antibody and caspase-3 fusion protein.
    Zhang DX, Zhao PT, Xia L, Liu LL, Liang J, Zhai HH, Zhang HB, Guo XG, Wu KC, Xu YM, Jia LT, Yang AG, Chen SY, Fan DM.
    Gut; 2010 Mar 15; 59(3):292-9. PubMed ID: 19951902
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Enhanced inhibition of murine tumor and human breast tumor xenografts using targeted delivery of an antibody-endostatin fusion protein.
    Cho HM, Rosenblatt JD, Kang YS, Iruela-Arispe ML, Morrison SL, Penichet ML, Kwon YG, Kim TW, Webster KA, Nechustan H, Shin SU.
    Mol Cancer Ther; 2005 Jun 15; 4(6):956-67. PubMed ID: 15956253
    [Abstract] [Full Text] [Related]

  • 20. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers.
    Pegram M, Hsu S, Lewis G, Pietras R, Beryt M, Sliwkowski M, Coombs D, Baly D, Kabbinavar F, Slamon D.
    Oncogene; 1999 Apr 01; 18(13):2241-51. PubMed ID: 10327070
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.